Management of bleeding complications of hematologic malignancies

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 4, 2007, Pages 427-434

  Green, David ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Bleeding; Blood products; Hematologic malignancies; Hemostasis; Platelets

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; DESMOPRESSIN; FIBRINOGEN; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; VITAMIN K GROUP;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ARTIFICIAL EMBOLISM; BLEEDING; BLOOD VISCOSITY; BRADYCARDIA; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DRUG HYPERSENSITIVITY; FATIGUE; FLUSHING; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPONATREMIA; HYPOTENSION; IMMUNOADSORPTION; LOW LEVEL LASER THERAPY; NAUSEA; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; VITAMIN K DEFICIENCY; VOMITING; WATER RETENTION; WOUND DRESSING;

BLOOD COAGULATION DISORDERS; DISEASE MANAGEMENT; HEMATOLOGIC NEOPLASMS; HEMORRHAGE; HUMANS; THROMBOCYTOPENIA;

EID: 34249940911     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-976178     Document Type: Review

References (33)

1. Elting LS, Martin CG, Kurtin DJ, et al. The bleeding risk index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors. Cancer 2002;94:3252-3262
2. Ey FS, Goodnight SH. Bleeding disorders in cancer. Semin Oncol 1990;17:187-197
3. Tallman M, Abutalib SA, Altman JK. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia. Semin Thromb Hemost 2007;33:330-338
4. Federici AB. Acquired von Willebrand Syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliterative and myeloproliferative disorders. Semin Hematol 2006;43(suppl 1):S48-S58
5. Pereira J, Phan T. Management of bleeding in patients with advanced cancer. Oncologist 2004;9:561-570
6. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1519-1538
7. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-4114
8. Brubaker DB, Marcus C, Holmes E. Intravascular and total body platelet equilibrium in healthy volunteers and in thrombocytopenic patients transfused with single donor platelets. Am J Hematol 1998;58:165-176
9. Downes KA, Wilson E, Yomtovian R, Sarode R. Serial measurement of clotting factor in thawed plasma stored for 5 days. Transfusion 2001;41:570
10. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987;69:1691-1695
11. Sallah S, Nguyen NP, Abdallah JM, Hanrahan LR. Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med 2000;124:730-734
12. Budde U, Dent JA, Berkowitz SD, et al. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 1986;68:1213-1217
13. Gabriel DA, Li X, Monroe DM III, Roberts HR. Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J Thromb Haemost 2004;2:1816-1822
14. Hoffman M, Monroe DM III, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 1(suppl):S21-S25
15. Hay CR, Negrier C, Ludlam C. The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: a multicenter study. Thromb Haemost 1997;78:1463-1467
16. Poon M-C. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa? Curr Hematol Rep 2003;2:139-147
17. Richardson P. Hemostatic complications of hematopoietic stem cell transplantation: from hemorrhage to microangiopathies and VOD. Pathophysiol Haemost Thromb 2003; 33(suppl 1):50-53
18. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-298
19. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004;2:1700-1708
20. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-785
21. Turecek PL, Varadi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia 2004;10(suppl 2):3-9
22. Luu H, Ewenstein B. FEIBA® safety profile in multiple modes of clinical and hone-therapy application. Haemophilia 2004;10(suppl 2):10-16
23. Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997;77:1113-1119
24. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002;8: 83-90
25. Berntorp E, Donfield S, Waters J, et al. The FEIBA® NovoSeven® Comparative Study (FENOC) - a randomized evaluation of by-passing agents in hemophilia complicated by inhibitors. Blood 2005;106:98a (abst)
26. Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998;92:2707-2711
27. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-755
28. Glick R, Green D, Ts'ao C, Witt W, Yu A, Raimondi A. High dose epsilon-aminocaproic acid prolongs the bleeding time and increases rebleeding and intraoperative hemorrhage in patients with subarachnoid hemorrhage. Neurosurgery 1981;9:398-401
29. Brown JE, Olujohungbe A, Chang J, et al. All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukemia. Br J Haematol 2000;110:1010-1012
30. Federici AB, Rand JH, Bucciarelli P, et al. Subcommittee on von Willebrand factor: acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84:345-349
31. Pineda AA, Vamvakas EC. Applications of therapeutic apheresis in patients with malignant disease. Oncologist 1997;2:94-103
32. Snyder HW, Cochran SK, Balint JP, et al. Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood 1992;79:2237-2245
33. Dzik WH, Duncan LM. Case 35-1994-A 55-year-old woman with a skin rash and hemiparesis after staphylococcal protein A column therapy. N Engl J Med 1994;331:792-800